药师参与急诊科癫痫持续状态抗癫痫药物治疗
该回顾性单中心观察研究纳入2018年1月至2020年7月急诊科成人癫痫持续状态患者20例,比较药师在场(13例)与不在场(7例)时抗癫痫药物给药时间及合理用药情况。药师在场组首剂与第二剂抗癫痫药物中位时间分别为26分钟(IQR 17-177)与51分钟(IQR 30-221),不在场组分别为37分钟(IQR 21-206)与171分钟(IQR 99-433),首剂P=0.58,第二剂P=0.07。药师在场组劳拉西泮当量中位剂量更高(2.5 mg [IQR 2-4] vs 2 mg [IQR 2-2],P=0.04),接受至少4 mg劳拉西泮当量的比例更高(38% vs 0%,P=0.11)。两组住院时间及30天死亡率无差异。
要点
- 药师在场组首剂抗癫痫药物中位给药时间26分钟(IQR 17-177),不在场组37分钟(IQR 21-206),P=0.58。
- 药师在场组第二剂抗癫痫药物中位给药时间51分钟(IQR 30-221),不在场组171分钟(IQR 99-433),P=0.07。
- 药师在场组劳拉西泮当量中位剂量2.5 mg(IQR 2-4),高于不在场组的2 mg(IQR 2-2),P=0.04。
- 药师在场组接受至少4 mg劳拉西泮当量的比例为38%,不在场组为0%,P=0.11。
- 两组住院时间及30天死亡率无差异。
适用人群与场景
- 2018年1月至2020年7月就诊于急诊科的成人癫痫持续状态患者。
研究设计与关键结果
- 研究类型:回顾性、单中心、观察性研究;样本量20例,药师在场组13例,不在场组7例。
- 主要结局:首剂抗癫痫药物中位给药时间药师在场组26分钟(IQR 17-177)vs 不在场组37分钟(IQR 21-206),P=0.58;第二剂中位给药时间药师在场组51分钟(IQR 30-221)vs 不在场组171分钟(IQR 99-433),P=0.07。
- 次要结局:两组合理选择抗癫痫药物无差异;药师在场组劳拉西泮当量中位剂量2.5 mg(IQR 2-4)vs 不在场组2 mg(IQR 2-2),P=0.04;接受至少4 mg劳拉西泮当量的比例药师在场组38% vs 不在场组0%,P=0.11。
- 两组住院时间及30天死亡率无差异。
证据类型、等级与局限
- 证据类型:回顾性、单中心、观察性研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为药师参与癫痫持续状态患者管理可能与抗癫痫药物给药时间临床显著缩短相关。
- 作者认为药师在场时药物剂量更符合指南,更多患者接受至少4 mg劳拉西泮当量。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
UNLABELLED: Background Despite there being an estimated 50,000-150,000 emergency department (ED) visits per year related to status epilepticus, there are limited data regarding pharmacist involvement in patient care. The purpose of this study was to evaluate differences in time to antiepileptic drug (AED) administration and appropriate AED use and dose when a pharmacist was present or not.
METHODS: Retrospective, single-center, observational study of adult status epilepticus patients presenting to the ED between January 2018 through July 2020. The primary outcome was time to AED administration. Secondary outcomes included occurrence of appropriate AED selection and dose, escalation of care, length of stay (LOS), and 30-day mortality. Wilcoxon rank-sum was used for continuous variables and nominal data was analyzed by Chi-square or Fisher's Exact test, as appropriate.
RESULTS: Twenty patients were included; 13 in the pharmacist-present and seven patients in the no-pharmacist-present groups. Median time to first and second AED was 26 min (IQR 17-177) versus 37 min (IQR 21-206), p = 0.58, and 51 min (IQR 30-221) versus 171 min (IQR 99-433), p = 0.07, in the pharmacist-present and no-pharmacist-present groups, respectively. Although there was no difference between groups for appropriate AED selection, those in the pharmacist-present group received a higher median dose of lorazepam equivalents (2.5 mg [IQR 2-4] vs 2 mg [IQR 2-2]; p = 0.04) and were more likely to receive at least 4 mg of lorazepam equivalents (38% vs 0%; p = 0.11). There were no differences in hospital LOS or 30-day mortality.
CONCLUSION: Pharmacist presence during status epilepticus patient management was associated with a clinically significant reduction in time to administration of AEDs. Medication doses were more guideline adherent and more patients received a lorazepam dose of at least 4 mg compared to when a pharmacist was not present.
参考来源
- Gawedzki P, Celmins L, Fischer D, et al. Pharmacist involvement with antiepileptic therapy for status epilepticus in the emergency department. Am J Emerg Med. 2022. PMID: 35841846. doi:10.1016/j.ajem.2022.07.002
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。